Skip to main content

Table 1 GSTT2 polymorphisms and colorectal cancer risk

From: GSTT2 promoter polymorphisms and colorectal cancer risk

Locus

HWE

MAF

Genotype

Healthy controls (N = 568)

CRC patients (N = 436)

p

OR(95% CI)

-537

0.999

0.42

GG

203 (35.7%)

127 (29.1%)

0.025

1.373 (1.041–1.810)

   

GA or AA

365 (64.3%)

309 (70.9%)

  

-277

0.548

0.07

TT

489 (86.1%)

388 (89.0%)

0.125

0.735 (0.495–1.090)

   

TC or CC

79 (13.9%)

48 (11.0%)

  

-158

0.314

0.03

GG

522 (91.9%)

416 (95.4%)

0.032

0.539 (0.307–0.947)

   

GA or AA

46 (8.1%)

20 (4.6%)

  
  1. Adjusted for age and sex; HWE: Hardy-Weinberg equilibrium for controls; MAF: Minor allele frequency
  2. Dominant model: Homozygote of major allele vs. heterozygote and homozygote of minor allele